External Source

Understanding Larotrectinib’s Safety Profile

2019 2:40
Synopsis
David S. Hong, MD, shares insight into the safety profile of larotrectinib, a tropomyosin receptor kinase (TRK) inhibitor, given data ...

You Might Also Like

Larotrectinib Is Well-Tolerated in Metastatic Solid Tumors 0:39
Larotrectinib Is Well-tolerated In Metastatic Solid Tumors
2020
Safety and Efficacy Profile for TRKi–Larotrectinib 4:54
Safety And Efficacy Profile For Trki–larotrectinib
2019
Favorable Safety Profile in Novel TRK Inhibitor 3:30
Favorable Safety Profile In Novel Trk Inhibitor
2019
Dr. Patel on the Safety Profile of Entrectinib in NTRK+ Solid Tumors 1:25
Dr. Patel On The Safety Profile Of Entrectinib In Ntrk+ Soli...
2020
Dr. van Tilburg on Larotrectinib in TRK+ Pediatric Cancers 0:52
Dr. Van Tilburg On Larotrectinib In Trk+ Pediatric Cancers
2019
The impact of TRK inhibitor LOXO-101 (larotrectinib) on patients with TRK fusion cancers 0:52
The Impact Of Trk Inhibitor Loxo-101 (larotrectinib) On Pati...
2017
Dr. Drilon Discusses the FDA Approval of Larotrectinib 0:54
Dr. Drilon Discusses The Fda Approval Of Larotrectinib
2018
Copy of Dr. Drilon Discusses the FDA Approval of Larotrectinib 0:21
Copy Of Dr. Drilon Discusses The Fda Approval Of Larotrectin...
2018
Larotrectinib in adult and pediatric patients with TRK fusion-positive primary CNS tumors 3:18
Larotrectinib In Adult And Pediatric Patients With Trk Fusio...
2021
Dirty Kinases in TRK-Fusion Malignancies 4:42
Dirty Kinases In Trk-fusion Malignancies
2019
TRK Inhibitor in GI Cancers: Adverse Effect Profile 5:20
Trk Inhibitor In Gi Cancers: Adverse Effect Profile
2020
Download Options
Choose a download method below. All links open in new tabs.
Service Features Action
SaveFrom
MP4 & MP3 • HD Quality • Browser Extension Available
Download
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.